Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab

Natalizumab is highly effective in the treatment of relapsing multiple sclerosis patients. Unfortunately, after stopping natalizumab, there is an increased risk of inflammation in the central nervous system and relapses. Switching from natalizumab to an alternative sufficient drug may prevent diseas...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis and related disorders 2018-05, Vol.22, p.87-89
Main Authors: Hümmert, Martin W., Deppe, Julian, Pul, Refik, Wurster, Ulrich, Schwenkenbecher, Philipp, Sühs, Kurt-Wolfram, Bronzlik, Paul, Stangel, Martin, Skripuletz, Thomas
Format: Article
Language:English
Subjects:
Alemtuzumab
Daclizumab
Multiple sclerosis
Natalizumab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Natalizumab is highly effective in the treatment of relapsing multiple sclerosis patients. Unfortunately, after stopping natalizumab, there is an increased risk of inflammation in the central nervous system and relapses. Switching from natalizumab to an alternative sufficient drug may prevent disease reactivation. Here we present a case of a patient who experienced a dramatic course with severe central nervous system inflammation after discontinuation of natalizumab and treatment initiation with daclizumab. During a treatment of 36 days, 20 g intravenous methylprednisolone in total and ten courses of plasmapheresis were not able to control the severe CNS inflammation. Alemtuzumab, which targets the whole lymphocyte population, was able to stabilize the devastating disease course in our case. •Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab.•Alemtuzumab was able to stabilize a devastating disease course.•Alemtuzumab represents a powerful drug after the use of daclizumab in patients with highly active multiple sclerosis.
ISSN:2211-0348
2211-0356
DOI:10.1016/j.msard.2018.03.021